文献速递头颈部肿瘤放疗姑息放疗与转移瘤

鼻咽癌临床试验的全球分布差异

Global Disparities in Current Clinical Trials in Nasopharyngeal Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-03

该研究基于ClinicalTrials.gov分析了2013至2023年间266项鼻咽癌2期和3期临床试验,发现试验主要来自中国(80%),放疗相关试验仅占9%,且低收入流行国家严重代表性不足。

要点

  • 鼻咽癌临床试验中免疫/靶向治疗占50%,化疗占30%,放疗仅占9%。
  • 仅5个流行国家参与国际试验,其中4个为高/中高收入国家。
  • 流行国家每绝对发病率的试验数显著少于非流行国家(P < .001)。

核心结论

  • 鼻咽癌临床试验分布存在显著差异,未能反映全球疾病负担和放疗的核心作用,低收入流行国家代表性严重不足。

研究设计与样本

  • 利用ClinicalTrials.gov对2013至2023年成人鼻咽癌2期和3期临床试验进行特征分析。
  • 流行国家定义为年龄标化发病率高于全球年龄标化发病率1.3/10万人年(基于GLOBOCAN 2022数据库)。

主要发现

  • 共266项临床试验纳入分析,干预措施为免疫/靶向治疗133项(50%)、化疗79项(30%)、放疗25项(9%)。
  • 试验主要来源为中国(80%),其次为美国(4.5%)和新加坡(1.5%)。
  • 29个鼻咽癌流行国家中仅5个(17%)参与了11项国际试验,其中4个(80%)为高收入和中高收入国家。
  • 24个代表性不足的流行国家中18个(75%)为较低收入国家。
  • 流行国家每绝对发病率的试验数显著少于非流行国家(P < .001),较低收入国家显著少于较高收入国家(P < .001),在主要测试放疗的试验子集中也观察到类似差异。

临床怎么用

  • 应加强区域和全球合作,促进低资源地区的患者和研究者参与鼻咽癌临床试验及全球对话。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nasopharyngeal carcinoma (NPC) is characterized by a distinct geographic distribution, with more than 90% of worldwide incidence and mortality occurring in East/Southeast Asia and Northern Africa. Clinical trials that inform evidence-based care must represent the target population of NPC; however, little is known about their geographic distribution and the extent to which they investigate radiation therapy (RT), which plays a central role in NPC management. METHODS AND MATERIALS: Using ClinicalTrials.gov, we characterized phase 2 and 3 clinical trials on adult patients with NPC from 2013 to 2023. Endemic countries were defined as having an age-standardized incidence rate higher than the world age-standardized incidence rate of 1.3 per 100,000 person-years using the Global Cancer Observatory (GLOBOCAN) 2022 database. RESULTS: There were 266 clinical trials eligible for analysis. Trial interventions were immunotherapy/targeted therapy in 133 (50%), chemotherapy in 79 (30%), and RT in 25 (9%). Trials most commonly originated from China (80%), followed by the United States (4.5%) and Singapore (1.5%). Of the 29 NPC-endemic countries, only 5 (17%) are represented in the 11 international trials-China (including Taiwan, Hong Kong, and Macau), Malaysia, Singapore, Thailand, and Tunisia-4 (80%) of which are high- and upper-middle-income countries. In contrast, 18 (75%) out of the 24 underrepresented endemic countries are lower-income. Trials per absolute NPC incidence were significantly fewer in endemic versus nonendemic countries (P < .001) and in lower- versus higher-income countries (P < .001). Similar disparities were observed in the subset of trials that primarily tested RT. CONCLUSIONS: The current NPC clinical trial landscape demonstrates significant disparities that do not reflect the global distribution of disease burden and the central role of RT. Lower-income endemic countries are severely underrepresented. Enhanced regional and global collaboration is critical in fostering the inclusion of both patients and researchers from lower-resourced settings in clinical trials and in the global NPC dialogue.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jainar CJE, Jacomina LE, Dee EC, et al. Global Disparities in Current Clinical Trials in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2025. PMID: 40614784. doi:10.1016/j.ijrobp.2025.06.3870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。